# PRE-DETERMINE: Advancing Sudden Arrhythmic Death Prediction in Coronary Artery Disease in the Absence of Severe Systolic Dysfunction

> **NIH HL R01** · CEDARS-SINAI MEDICAL CENTER · 2026 · $1,491,021

## Abstract

Sudden and/or arrhythmic death (SAD), which typically results from lethal ventricular arrhythmias (ventricular
tachycardia and ventricular fibrillation, VT/VF) in the setting of coronary heart disease (CHD), afflicts an
estimated 310,000 persons annually in the United States. Reductions in SAD have continued to lag those
observed for other coronary heart disease (CHD) outcomes despite advances in resuscitation therapies and
the use of implantable cardioverter-defibrillators (ICDs). Current approaches to SAD prevention remain
centered on placing ICDs in patients with left ventricular ejection fraction (LVEF) <30-35% – even though the
majority of SAD occurs in the setting of LVEF >30-35%. In effect, the proportionately larger segment of the
at-risk population has been understudied and thus undertreated. Despite this unmet need, there remain very
few, if any, prospective studies examining SAD risk prediction in individuals with CHD and LVEF >30-35% over
a long enough time horizon where ICD therapy might be cost-effective. For this very reason, the PRE-
DETERMINE Cohort Study was intentionally designed to address this scientific gap and prospectively
study clinically relevant approaches to SAD risk prediction in CHD patients with LVEF >30-35%. In this
application, we propose to leverage the originally NHLBI-funded base cohort resource to continue adjudication
of accruing SAD and VT/VF events, in addition to competing causes of death, to attain 10+ years of endpoint
adjudication to enable the development and validation of multi-marker SAD risk prediction models based on
combinations of multi-dimensional clinical, ECG, imaging, biomarker, and genetic data generated in this unique
multicenter cohort of 5761 CHD patients. We will also leverage the base cohort to interrogate novel fatty acid
derived eicosanoids and putative arrhythmia modulating proteomic analytes in relation to risk for SAD and
competing causes of mortality in patients with CHD. Novel methods of competing r

## Key facts

- **NIH application ID:** 11261237
- **Project number:** 5R01HL165840-04
- **Recipient organization:** CEDARS-SINAI MEDICAL CENTER
- **Principal Investigator:** CHRISTINE M ALBERT; Susan  Cheng; Brian  Claggett
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** HL
- **Fiscal year:** 2026
- **Award amount:** $1,491,021
- **Award type:** 5
- **Project period:** 2023-02-15T00:00:00 → 2027-01-31T00:00:00

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11261237

## Citation

> US National Institutes of Health, RePORTER application 11261237, PRE-DETERMINE: Advancing Sudden Arrhythmic Death Prediction in Coronary Artery Disease in the Absence of Severe Systolic Dysfunction (5R01HL165840-04). Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/grant/nih/11261237. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*